Syntocinon ( DrugBank: - )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 1 |
| 127 | 前頭側頭葉変性症 | 1 |
| 193 | プラダー・ウィリ症候群 | 7 |
6. パーキンソン病
臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-002877-23-AT (EUCTR) | 21/01/2019 | 07/12/2018 | Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study. - Oxytocin in healthy controls and PD | Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study. - Oxytocin in healthy controls and PD | Social functioning in Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Syntocinon 40 IU/ml nasal spray INN or Proposed INN: Synthetic Oxytocin Other descriptive name: OXYTOCIN SYNTHETIC | Abteilung für Neurologie der Medizinischen Universität Innsbruck | NULL | Not Recruiting | Female: no Male: yes | 76 | Phase 2 | Austria |
127. 前頭側頭葉変性症
臨床試験数 : 89 / 薬物数 : 104 - (DrugBank : 33) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 117
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03260920 (ClinicalTrials.gov) | January 31, 2018 | 19/7/2017 | Intranasal Oxytocin for Frontotemporal Dementia | A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia | Frontotemporal Dementia | Drug: Syntocinon | Lawson Health Research Institute | Weston Brain Institute;Canadian Institutes of Health Research (CIHR);Berry Consultants | Recruiting | 30 Years | 80 Years | All | 112 | Phase 2 | United States;Canada |
193. プラダー・ウィリ症候群
臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-003423-30-NL (EUCTR) | 12/12/2017 | 04/10/2017 | Intranasal administration of oxytocin in children with Prader-Willi syndrome | Randomized, double-blind, placebo-controlled oxytocin and dose-response trial in children with Prader-Willi syndrome.Effects on social behaviour. | Prader-Willi syndrome MedDRA version: 20.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Syntocinon nasal spray Product Name: oxytocin Product Code: oxytocin | Dutch Growth Research Foundation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 33 | Phase 2;Phase 3 | Netherlands | ||
| 2 | EUCTR2016-003820-22-NL (EUCTR) | 22/12/2016 | 12/10/2016 | Intranasal administration of oxytocin in children with Prader-Willi Syndrome | Intranasal administration of oxytocin in children with Prader-Willi Syndrome. A randomized, open-label, cross-over trial of different treatment regimens of oxytocin administration. Effects on eating behaviour and social behaviour. - Intranasal administration of oxytocin in children with PWS | Prader-Willi syndrome MedDRA version: 19.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Syntocinon nasal spray Product Name: oxytocin Product Code: oxytocin | Dutch Growth Research Foundation | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Netherlands | |||
| 3 | EUCTR2016-003273-18-FR (EUCTR) | 14/11/2016 | 22/08/2016 | Oxytocin intranasal administrations in children with Prader-Willi syndrome aged from 3 to 12 years. | Effects of intranasal administrations of oxytocin on beahvioural troubles, hyperphagia and social skills in children with Prader-Willi syndrome aged from 3 to 12 years. - OXYJEUNE | Prader-Willi Syndrom;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Syntocinon | University Hospital of Toulouse | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | France | ||
| 4 | EUCTR2013-004134-15-NL (EUCTR) | 15/07/2014 | 20/03/2014 | Intranasal administration of oxytocin in children and young-adults with Prader-Willi syndrome | Intranasal administration of oxytocin in children and young adults with Prader-Willi Syndrome. A randomized, double-blind, placebo-controlled trial. Effects on satiety and food intake, and social behaviour. - Intranasal administration of oxytocin in PWS | Prader-Willi syndrome MedDRA version: 17.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Syntocinon nasal spray Product Name: oxytocin Product Code: oxytocin | Dutch Growth Research Foundation | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Netherlands | |||
| 5 | EUCTR2013-004437-33-FR (EUCTR) | 18/03/2014 | 08/09/2015 | Effets de l'administration intranasale répétée d'ocytocine chez des patients adultes présentant un syndrome de Prader-Willi | Effets de l'administration intranasale répétée d'ocytocine chez des patients adultes présentant un syndrome de Prader-Willi. - PRADOTIM | Prader-Willi syndrom MedDRA version: 18.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Syntocinon | Centre Hospitalier de Toulouse | NULL | Not Recruiting | Female: yes Male: yes | 39 | Phase 3 | France | ||
| 6 | NCT01038570 (ClinicalTrials.gov) | June 2009 | 16/11/2009 | Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo | Evaluation of the Effect of the Oxytocin Administered in Nasal Pulverizing on the Social Skills, the Stress, the Anxiety and the Eating Habits at Grown-up Patients Presenting a Syndrome of Prader-Willi: Pilot Study | Prader Willi Syndrome | Drug: Syntocinon®/- Spray;Drug: Physiological serum (Sodium chloride) | University Hospital, Toulouse | NULL | Completed | 18 Years | N/A | All | 24 | Phase 2 | France |
| 7 | EUCTR2010-022370-14-FR (EUCTR) | 15/11/2010 | Evaluation de la tolérance d'une administration intra-nasale d'ocytocine chez des nourrissons présentant un syndrome de Prader-Willi et de son effet sur la succion et la prise alimentaire. - OTBB | Evaluation de la tolérance d'une administration intra-nasale d'ocytocine chez des nourrissons présentant un syndrome de Prader-Willi et de son effet sur la succion et la prise alimentaire. - OTBB | Syndrome de Prader Willi MedDRA version: 12.1;Level: LLT;Classification code 10036476;Term: Prader-Willi syndrome | Trade Name: Syntocinon | Centre Hospitalier de Toulouse | NULL | NA | Female: yes Male: yes | Phase 2 | France |